THERAPY DOSSIER · th-474e6d2a5544

Pectolinarigenin

Nutraceutical

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Spinal cord injury
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 31007732 ↗2019Reported benefit

Pectolinarigenin promotes functional recovery and inhibits apoptosis in rats following spinal cord injuries.

RatSpinal cord injuryContusionSprague-DawleyMalen = 36 rats in six groups of sixIntraperitoneal10, 30 and 50 mg/kgAfter injury

Model: Acute spinal cord injury by T10 laminectomy and a modified Allen method dropping a 10 g rod from 4 cm onto the dorsal cord surface

Pectolinarigenin improved locomotor scores dose dependently, increased surviving neurons, reduced TUNEL-positive cells and lowered apoptosis-related proteins, with 50 mg/kg comparable to methylprednisolone.

Extraction: extract · Subtype source: llm · Supplied extraction confidence: 0.9. Machine-extracted fields require source verification.

Loading the evidence…